Our CEO Fabrice Chouraqui and Rob Coker of The Medicine Maker discuss how the Cellarity platform is using #AI and #ML to re-envision #DrugDiscovery for the better—and the impact approaches like ours could have on people living with disease and in need of new therapies. Read the Q&A: https://lnkd.in/eAGmU5kv #ArtificialIntelligence #MachineLearning
Cellarity
Biotechnology Research
Somerville, MA 13,608 followers
Rewriting the rules of drug creation
Über uns
Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas including those in metabolic disease, hematology, and immuno-oncology.
- Website
-
http://www.cellarity.com
External link for Cellarity
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- Somerville, MA
- Typ
- In Privatbesitz
- Gegründet
- 2017
- Spezialitäten
- Drug Discovery, Drug Development, Single Cell Technologies, AI, Artificial Intelligence, and Machine Learning
Standorte
-
Primäre
Wegbeschreibung erhalten
101 South Street 6th Floor
Somerville, MA 02143, US
Employees at Cellarity
Aktualisierungen
-
We’re focusing on the whole cell rather than single molecular targets to transform drug discovery. Our CEO Fabrice Chouraqui shares how we’ve created a drug candidate with gene-therapy-like efficacy in a once-daily pill to treat sickle cell disease. Learn more via Pharmaceutical Executive: https://bit.ly/4cO02UL #DrugDiscovery #MachineLearning #SickleCellDisease #SingleCell
-
Our CEO Fabrice Chouraqui explains the power of our drug discovery platform in a new interview with Pharmaceutical Executive. Listen here: https://bit.ly/3WegtTc #DrugDiscovery #MachineLearning #AI #SingleCell
How Cellarity's AI/ML Approach Differs
pharmexec.com
-
We're thrilled to announce that we've appointed Percy Carter, MBA, Ph.D., to our Board of Directors! Dr. Carter has a strong track record of shaping and leading drug discovery and platform development. His leadership will help accelerate our work to bring value to patients via novel biology and differentiated drug candidates. Welcome, Percy!
Cellarity Appoints Percy Carter, MBA, Ph.D., as Member of Board of Directors
businesswire.com
-
Exciting news from Flagship Pioneering as they announce the raise of $3.6 billion to fuel breakthrough innovations that transform human health and sustainability. We are proud to be #FlagshipFounded and part of an ecosystem of companies – present and future – taking bold scientific leaps to deliver a better future for all.
Flagship Pioneering raises $3.6 billion to fuel critical breakthroughs in human health and sustainability. This expanded capital pool will accelerate the impact of original science and the creation and development of an estimated 25 breakthrough companies in human health, sustainability, and artificial intelligence. Hear from Flagship Founder and CEO Noubar Afeyan about how we're taking #BiggerLeaps by leveraging the power of generative AI, forging novel partnerships with pharma to speed drug development, expanding globally, and promoting and hiring top talent to our leadership ranks. Read the full press release: https://bit.ly/4eQfx05
-
Our CEO Fabrice Chouraqui tells Drug Target Review how we’re leveraging #AI to transform #DrugDiscovery and tackle diseases like never before. Read the full article:
Changing the paradigm of drug discovery processes with AI
https://www.drugtargetreview.com
-
We're excited to share that our CEO, Fabrice Chouraqui, was featured in a recent STAT interview! Fabrice discussed how Cellarity is leveraging multi-omics data and artificial intelligence to shift the focus from single molecular targets to the cellular dysfunction underlying diseases. Our new approach has led to the development of candidates for #SickleCellDisease and autoimmune diseases. Discover the future of health care and innovation by reading the full interview: https://lnkd.in/eB_uatfF
Q&A: How Flagship’s Cellarity is using AI to understand cell disease biology before treating it
https://www.statnews.com
-
#SickleCellDisease is a devastating, inherited blood disease that impacts 5M+ people around the world, leading to excruciating pain crises and other health complications. Our most advanced program is in #SickleCell. We are proud to be part of an ecosystem including organizations like #ThroughThePain and others working tirelessly to advocate for better care, support and research around this disease. Together, we can create #HopeThroughProgress. Learn more about this disease and our ongoing work to give these patients hope at Cellarity: https://bit.ly/4evHPgc #WorldSickleCellDay
-
Our CEO, Fabrice Chouraqui, recently sat down with Axios to discuss how we’re using the transformative power of #AI and #ML to gain deeper insights into disease biology – so we can revolutionize drug creation. Read the full interview: https://lnkd.in/ere5xNzD
Axios Future of Health Care - Axios interview: Drug discovery revolution
axios.com
-
We are delighted to welcome Christopher Woelk ("Topher") to our team as our new VP and Head of Platform! Topher brings with him a wealth of expertise in powerful techniques that lead to new target identification and biomarker discovery. As Head of Platform, he will shape the strategy of our end-to-end AI platform to help us unlock a new paradigm of drug creation. Welcome, Topher!
Cellarity Appoints Head of Platform to Advance Vision for Novel Drug Creation
businesswire.com